Key Insights

Highlights

Treatment Research

4 treatments under study, led by Raav2tyfgrk1hrpgrco

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 1/2 (1)
Phase 2 (1)
Phase 2/3 (1)

Trial Status

Active Not Recruiting2
Recruiting1
Unknown1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07174726Phase 2Active Not RecruitingPrimary

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT04850118Phase 2/3Active Not Recruiting

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

NCT06982417Recruiting

InsightRP2 Registry

NCT06492850Phase 1/2UnknownPrimary

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

Showing all 4 trials

Research Network

Common Treatments

  • Raav2tyfgrk1hrpgrco1
  • Adenoassociated Virus Vector Expressing A Human Rpgr Gene1
  • Control1
  • Ft0021

Active Sponsors

  • Beacon Therapeutics2
  • Beacon Therapeutics (USA) Inc.1
  • University of Göttingen1
  • Frontera Therapeutics1

Top Investigators

Related Conditions

  • Rp2associated Retinitis Pigmentosa1
  • Retinitis Pigmentosa 21
  • Xlinked Retinitis Pigmentosa1

Activity Timeline